The Journal of Pharmacology and Experimental Therapeutics
Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009
And the company "disclaims any liability for the medical or pharmaceutical services provided through its platform." Spotting red flags While the Ousia situation is unfortunate for the patients involved, it's an example of the regulatory system working the way it's supposed to, says Brunner
Strategies on how to manage these and other side effects are described in more detail here: Figure 3 of this article and Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists
Drug formularies may cover GLP-1 agonists prescribed for Type 2 diabetes but not for weight loss
